Brivaracetam Dosing in Hemodialysis
No dose adjustment is required for brivaracetam in patients on hemodialysis, as less than 10% of the drug is excreted unchanged in the urine and hemodialysis is not expected to significantly enhance clearance.
Pharmacokinetic Rationale
Brivaracetam has favorable pharmacokinetic properties that make renal dosing adjustments unnecessary 1:
- Minimal renal excretion: Less than 10% of brivaracetam is excreted unchanged in the urine
- Primarily hepatic metabolism: The drug is eliminated predominantly through hepatic metabolism via amidase-mediated hydrolysis and CYP2C19-mediated hydroxylation
- Low dialyzability: Because of minimal renal excretion, hemodialysis is not expected to enhance brivaracetam clearance
- Low protein binding: Brivaracetam is weakly bound to plasma proteins (≤20%), but the primary elimination pathway remains hepatic rather than renal
Dosing Recommendations
Standard Dosing Applies
For patients with focal seizures on hemodialysis:
- Initial dose: 50 mg twice daily (100 mg/day)
- Target dose: 50-100 mg twice daily (100-200 mg/day)
- No post-dialysis supplementation needed
- No timing restrictions relative to dialysis sessions
Dose Titration
- Start at 50 mg twice daily
- May increase to 100 mg twice daily based on clinical response and tolerability
- No specific titration schedule required—brivaracetam can be initiated at target dose 2
Clinical Efficacy Context
Brivaracetam demonstrates robust efficacy in focal seizures 3, 4:
- 50% responder rates: 32.7-55.8% at 50 mg/day; 36-38.9% at 100 mg/day; 37.8% at 200 mg/day
- Seizure freedom: Achieved in 21.3% of patients in real-world settings 5
- Rapid onset: Efficacy can be observed on day 1 of oral administration 2
Important Considerations
Drug Interactions
CYP2C19 considerations 1:
- CYP2C19 poor metabolizers may have 42% higher brivaracetam levels
- Consider dose reduction if patient is a known CYP2C19 poor metabolizer or taking strong CYP2C19 inhibitors
- This is independent of renal function
Tolerability Profile
Common adverse events include 3, 5, 4:
- Sedation/somnolence (most common reason for discontinuation)
- Dizziness
- Psychiatric effects (8.3% discontinuation rate)
- Generally well-tolerated with 64.3% retention in long-term studies
Levetiracetam Conversion
If converting from levetiracetam 5, 6:
- Use conversion ratio of 10:1 to 15:1 (levetiracetam:brivaracetam)
- Immediate switch is feasible
- May improve behavioral side effects associated with levetiracetam
- 64.2% of patients who failed levetiracetam benefited from brivaracetam
Contrast with Other Antiseizure Medications
The provided evidence includes extensive guidance on tuberculosis medications requiring renal dose adjustments 7, 8, 7, which serves to highlight that brivaracetam's pharmacokinetic profile is fundamentally different—it does not require the frequency adjustments or post-dialysis timing considerations needed for renally-cleared medications.